Long-term Efficacy of Vedolizumab for Ulcerative Colitis
暂无分享,去创建一个
A. Kaser | S. Vermeire | D. Rubin | B. Sands | G. D'Haens | W. Sandborn | B. Feagan | E. Loftus | R. Panaccione | S. Danese | J. Colombel | I. Shafran | R. Mody | M. Smyth | M. McAuliffe | A. Kaviya | S. Sankoh | B. Abhyankar
[1] P. Rutgeerts,et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.
[2] T. Wyant,et al. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab , 2016, Cytometry. Part B, Clinical cytometry.
[3] C. Siegel,et al. Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial: 1859 , 2015 .
[4] A. Griffiths,et al. Methotrexate for maintenance of remission in ulcerative colitis. , 2015, The Cochrane database of systematic reviews.
[5] W. Sandborn,et al. Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease , 2015, Alimentary pharmacology & therapeutics.
[6] K. Garnock-Jones. Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease , 2015, BioDrugs.
[7] S. Bickston,et al. Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us? , 2014, Inflammatory bowel diseases.
[8] M. Dubinsky,et al. Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn’s Disease: 1618 , 2014 .
[9] Domján Andrea,et al. World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects , 2014 .
[10] U. Kopylov,et al. Optimizing anti-TNF treatments in inflammatory bowel disease. , 2014, Autoimmunity reviews.
[11] J. Provenzale,et al. Risk Assessment and Minimization for Progressive Multifocal Leukoencephalopathy (PML RAMP): A Program to Assess for Potential Early Signs and Symptoms of PML during Clinical Development of Vedolizumab: 1673 , 2013 .
[12] P. Rutgeerts,et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.
[13] J. Xu,et al. Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[14] K. Burke,et al. Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates , 2012, Inflammatory bowel diseases.
[15] R. Cross,et al. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. , 2012, Immunotherapy.
[16] W. Sandborn,et al. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] W. Sandborn,et al. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.
[18] C. Lees,et al. Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.
[19] S. Hanauer,et al. Assessing Response and Loss of Response to Biological Therapies in IBD , 2011, The American Journal of Gastroenterology.
[20] R. Egan,et al. The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.
[21] M. Kosinski,et al. Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease , 2009, Alimentary pharmacology & therapeutics.
[22] D. Rubin,et al. Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial , 2008, The American Journal of Gastroenterology.
[23] A. Timmer,et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.
[24] S. Travis,et al. Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.
[25] I. Vlachonikolis,et al. The Inflammatory Bowel Disease Questionnaire: A Review of Its National Validation Studies , 2004, Inflammatory bowel diseases.
[26] E. McColl,et al. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis , 2004, Quality of Life Research.
[27] H. König,et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease , 2002, European journal of gastroenterology & hepatology.
[28] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[29] C. Mackay,et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. , 1997, The American journal of pathology.
[30] C. Mackay,et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. , 1996, Gastroenterology.
[31] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.
[32] C. FordAlexander,et al. ULCERATIVE colitis. , 1997, Journal of the American Medical Association.